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committee (IKDC) scaleAbstract Osteoarthritis (OA) is the most prevalent form of arthritis in the world.
Aim of the work: To evaluate the effect of 6-monthly intra-articular injection of platelet rich
plasma (PRP) on the functional status of knee joint measured by the International Knee Document
Committee scale (IKDC), the visual analogue scale for pain (VAS) on the ultrasonographic ﬁndings
of OA knee. Assessment of its safety as a new line of treatment was taken into consideration.
Patients and methods: The study was carried out on 20 patients with mild to moderate primary
knee OA. They were injected intra-articularly with 5 ml PRP for each affected joint, at 1 month
intervals for 6 injections. Clinical examination, VAS, IKDC score and diagnostic Doppler ultraso-
nography were performed before and after PRP treatment.
Results: After 6 months of PRP, there was a signiﬁcant improvement in the duration of inactiv-
ity stiffness (8.3 ± 2.4 min), VAS score (3.9 ± 1.1) and IKDC score (74.3 ± 10.2) compared to
baseline values (18.7 ± 6.5 min, 5.9 ± 1.3 and 40.9 ± 10.4 respectively; p< 0.001). A signiﬁcant
improvement in Doppler activity (p= 0.04) and synovial thickening (p< 0.001) was found after
6 months of PRP. A signiﬁcant correlation was found between age of patients, body mass index
and disease duration with the VAS (r= 0.55, p< 0.001 and r= 0.29, p= 0.03 and r= 0.71,
120 A.S. Hassan et al.p< 0.001) and a negative correlation with the IKDC score (r= 0.32, p= 0.03, r= 0.96,
p< 0.001 and r= 0.79, p< 0.001 respectively).
Conclusion: Intra-articular injection of PRP is an effective and safe method for treatment of
knee OA. Maximal improvement is obtained in patients with young age and short disease duration.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.1. Introduction
Osteoarthritis (OA) is the most prevalent form of arthritis in
the world. With the progressive ageing of the population, it
becomes a major problem of public health. Osteoarthritis is
a degenerative affection characterised by many disorders lead-
ing to structural and functional defect of one or several joints
[1]. The combination of biochemical markers with clinical and
radiographic data was most helpful to improve the diagnostic
and prognostic values on assessment of patients with early
knee OA and in determining disease progression [2].
The management of chondral disease is challenging because
of its inherent low healing potential. In fact, the regeneration
ability of cartilage is limited due to its isolation from systemic
regulation and its lack of vessels and nerves [3]. Intra-articular
injection of Human umbilical cord blood as a new source of
mesenchymal stem cells was found effective for cartilage repair
in rats with osteoarthritis [4].
A variety of agents, such as nonsteroidal anti-inﬂammatory
drugs, glucosamine, chondroitin-sulphate, hyaluronic acid,
and glucocorticoids have been proposed as non-invasive
solutions for pain treatment, improvement in function, and
disability, and ultimately modiﬁcation of severe chondral
degeneration and osteoarthritis with varying success rates [5].
Glucosamine, chondroitin-sulphate, and intra-articular
hyaluronic acid have not been clearly demonstrated to be
effective, and due to the continuing controversies and lack of
common accepted beneﬁcial evidence they should not be con-
sidered ideal procedures for the treatment of chronic severe
chondropathies or osteoarthritis [6].
The ﬁeld of using platelet rich plasma (PRP) in clinical and
basic science research is growing. There is experimental evi-
dence for positive effects of PRP in the context of soft tissue
healing, ligament and bone regeneration, and inﬂammation
reduction [7–10]. In another study on Egyptian patients with
lateral epicondylitis and with plantar fasciitis, PRP was found
promising and effective in both [11].
The aim of this work was to evaluate the effect of 6-
monthly intra-articular injection of PRP on the functional
status of the knee joint as measured by the International Knee
Document Committee scale (IKDC), on the visual analogue
scale for pain (VAS) and on the ultrasonographic ﬁnding of
the OA knee. Assessment of its safety as a new line of
treatment in knee OA was taken into consideration.
2. Patients and methods
2.1. Patients
The study was carried out on 20 patients with mild to
moderate primary knee OA, recruited from Rheumatology
and Rehabilitation outpatient clinics in Zagazig UniversityHospitals, during the period from May 2012 to March 2013.
They were diagnosed according to The American College of
Rheumatology (ACR) classiﬁcation criteria of OA [12]. The
study was approved by the local ethics committee and by the
Institutional Review Board (IRB) of the institution. An
informed written consent was taken from all the participants.
Inclusion criteria for patients selection included history of
chronic (at least 4 months) pain or swelling of the knee, not
responding to NSAIDs and/or physical therapy and radio-
graphic ﬁndings of minimal (grade 1: deﬁnite osteophyte,
unimpaired joint space) to moderate (grade 2: moderate dimi-
nution of joint space) OA of the knee joint, according to Kell-
gren-Lawrence scale [13]. Exclusion criteria were systemic
disorders, such as diabetes, rheumatoid arthritis, major axial
deviation (varus more than 5 deg, valgus more than 5 deg),
haematological diseases (coagulopathies), severe cardiovascu-
lar diseases, infections, immunosuppression, patients on ther-
apy with anticoagulants–antiaggregants or use of NSAIDs
within 5 days before blood donation.2.2. Clinical, functional and radiological assessment
At the ﬁrst visit all patients were subjected to full history tak-
ing, general examination and complete knee joint examination.
The severity of pain was assessed by VAS [14]. Patients were
asked to complete the International knee documentation com-
mittee (IKDC) osteoarthritis scale in order to evaluate the
function of the affected knee [15]. Plain X-ray of the affected
knee, anteroposterior and lateral views were done for grading
of knee OA which was done according to the Kellgren–Law-
rence grading system [13].
Sonographic Doppler examination was performed on the
affected knee with 5.12 MHz linear array transducer (Medison
R3). Patients were supine on an examination bed, with the
knee ﬂexed as much as possible [16]. Ultrasonography reports
included comment on increased vascularity (Doppler activity),
synovial hypertrophy, cartilage thickness, regularity of the car-
tilage margins and effusion.
Ultrasonographic detection of cartilage degeneration of the
osteoarthritic knee was done according to Saarakkala et al.
[17], in which they recommended supine position and the knee
was fully ﬂexed. First, the intercondylar notch area, including
femoral condyles just above the patellar bone (later called sul-
cus), was depicted. Subsequently, the cartilage in medial and
lateral femoral condyles were fully scanned by sweeping the
full surfaces of the cartilage from proximal to distal with the
probe always in transverse position. The ultrasound beam
was kept perpendicular to the surface of the femur all the time.
They evaluated the cartilage and gave the following grades:
Grade 0: a monotonous anechoic band having sharp
hyperechoic anterior and posterior interfaces. Grade 1 (Mild
degenerative changes): loss of the normal sharpness of cartilage
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point for each observation site, thus maximum of three points
if the ﬁndings were present in both condyles and in the sulcus).
Grade 2A (Moderate degenerative changes): in addition to
above changes, clear local thinning (less than 50%) of the car-
tilage was observed. Grade 2B: degenerative changes were:
local thinning of the cartilage more than 50% but less than
100% (two points at each observation site, maximum of six
points). Grade 3 (Severe degenerative change): 100% local loss
of the cartilage tissue (three points, maximum of nine points).
Synovial hypertrophy was judged according to the Out-
come Measures in Rheumatoid Arthritis Clinical Trials
Ultrasonography Task force which reported the US deﬁni-
tion of synovial hypertrophy as ‘‘abnormal hypoechoic (rel-
ative to subdermal fat, but sometimes may be isoechoic or
hyperechoic) intraarticular tissue that is nondisplaceable
and poorly compressible and which may exhibit Doppler’’
[18].
All patients were injected intra-articularly with about 5 ml
of PRP for each affected joint, at 1 month intervals, for 6 injec-
tions. Injection was performed with the patient in the supine
position, with the knee fully extended, using the lateral
approach. After injection, patients were instructed not to use
the injected leg for 24 h, use ice packs over the injected joint
and not to use NSAIDs during this period [19].
2.3. Platelet – rich plasma preparation
The procedure consisted of 30 ml of venous blood samples
taken from every patient and collected in sterile sodium cit-
rated tubes. Platelet concentrates rich in growth factors were
obtained by the following technique: The tubes with citrated
blood were centrifuged at 1800 rpm for 15 min to separate
erythrocytes, and at 3500 rpm for 10 min to concentrate plate-
lets [20]. By this method, 5 ml of PRP were obtained and
injected immediately without storage. It has been stated that
using freshly-harvested PRP might preserve all the platelet
functions better [19].
2.4. Follow up assessment
After 6 months, all patients were re-evaluated by physical
examination, assessment of VAS for pain, IKDC score and
musculoskeletal Doppler ultrasonography.
Statistical analysis:Data of the patients were entered on the
Statistical Package for Social Science (SPSS). Quantitative
data were presented as mean and standard deviation, whileTable 1 Difference between clinical data of knee osteoarthri-
tis patients at base line and after 6 PRP injections.
Clinical data N (%) Base line After 6 months X2 P
Hotness 2 (20) 0 (0) 2.11 0.15
Tender joint line 13 (65) 6 (30) 4.91 0.02*
Crepitus 13 (65) 8 (40) 4.91 0.03*
Eﬀusion 1 (5) 0 (0) 1.03 0.31
Backer cyst 1 (5) 1 (5) 1.02 0.30
Limited ROM 7 (35) 2 (10) 3.95 0.04*
ROM: range of motion.
* Signiﬁcance at p< 0.05.the qualitative data were presented as number and percentage.
Paired t-test and chi square test were used to assess differences
between quantitative and qualitative data at baseline and after
6 PRP injections. Spearman’s correlation coefﬁcient analysis
was performed to identify factors associated with better func-
tional outcomes. A statistically signiﬁcant cutoff value was set
at p< 0.05.3. Results
3.1. Clinical data of patients
This study was carried out on 20 patients who were suffering
from mild to moderate primary knee OA diagnosed clinically,
by plain X-ray and Doppler musculoskeletal ultrasound. There
were 14 (70%) females and 6(30%) males. Their age ranged
from 40 to 70 years with a mean of 50.4 ± 8. Thirteen patients
were overweight with body mass index ranged from 22–35,
with a mean of 28.4 ± 7.7. Five patients were of normal
weight and two were obese. Their disease duration ranged
from 19–30 months, with a mean of 24 ± 5. Seventy percent
of patients had moderate OA (grade 2) and 30% had minimal
OA (grade 1), according to Kellgren-Lawrence scale. There
were statistically signiﬁcant differences in the number of
patients with crepitus, tenderness at the joint line and limited
ROM at base line and after 6 monthly injections of PRP
(p < 0.05) (Table 1).
3.2. Pain and functions of the affected joints
Table 2 shows clinical and functional changes of affected joint
after 6 PRP injections. There was a highly statistically signiﬁ-
cant improvement in the duration of inactivity stiffness; VAS
score and IKDC score (p < 0.001).
3.3. Changes in ultrasonographic ﬁndings
Patients did not show any signiﬁcant changes in the ultrasono-
graphic grading of cartilage degeneration after PRP injections.
While there was a signiﬁcant decrease in the number of
patients having increased Doppler activity after 6 PRP injec-
tions (p= 0.04), as 35% showed activity at baseline while only
10% showed it after 6 PRP injections. There was a highly sig-
niﬁcant decrease in the number of patients having synovial
hypertrophy .Only 5 cases (25%) had synovial hyperplasia
after 6 PRP injections, compared to 15 cases (75%) at baseline
(Table 3).
In this study, nine patients (45%) reported decreased use of
NSAIDs and/or physical therapy after 6 PRP injections.
Regarding complications, 5 patients (25%) experienced slight
pain at the site of injection which lasted for one week and only
one patient (5%) experienced marked pain. Two patients
(10%) had skin discolouration in the form of bruising. No
reported cases suffered from infection or allergic reaction.
3.4. Factors associated with improvement after PRP injections
The BMI showed a signiﬁcant correlation with VAS and a
highly signiﬁcant negative correlation with IKDC score after
6 PRP injections. Patient’s age and disease duration had a
Table 3 Differences in musculoskeletal US ﬁndings and grading after 6 PRP – injections in patients with knee osteoarthritis.
US ﬁndings N (%) Base line After 6 months X2 P
Doppler activity 7 (35) 2 (10) 4.23 0.04*
Grade 1 6 (30) 7 (35) 0.40 0.53
Grade 2 7 (35) 6 (30) 0.37 0.49
Grade 3 7 (35) 7 (35) 0.60 0.63
Synovial hypertrophy 15 (75) 5 (25) 4.91 <0.001**
* Signiﬁcance at p< 0.05.
** High signiﬁcance at p< 0.001.
Table 2 Effects of PRP injection on pain and function of affected joints in patients with knee osteoarthritis.
Mean ± SD (range) Base line After 6 months t P
Inactivity stiﬀness (min) 18.7 ± 6.5 (15–30) 8.3 ± 2.4 (4–10) 20.3 <0.001**
VAS (cm) 5.9 ± 1.3 (4–7) 3.9 ± 1.1 (2–4) 13.1 <0.001**
IKDC 40.9 ± 10.4 (30–40) 74.3 ± 10.2 (64–85) 21.5 <0.001**
VAS: visual analogue scale, IKDC: international knee documentation committee.
** High signiﬁcance at p< 0.001.
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negative correlation with the IKDC score (Table 4).
4. Discussion
Osteoarthritis is a major public health problem which causes
pain and disability in one third of all affected patients [21].
It is one of the crucial musculoskeletal disorders characterised
by the imbalanced homoeostasis and destruction of the articu-
lar cartilage, in which pro-inﬂammatory cytokines are impor-
tant catabolic regulators during OA cascade [22]. Platelet-
rich plasma (PRP) is a natural concentrate of autologous
growth factors from the blood. It allows in a simple, low cost
and minimally invasive way to obtain a concentration of many
growth factors [23]. The application of PRP to treat OA of the
knee can be considered a relatively new therapeutic indication
[24]. This study has been carried out on 20 patients suffering
from mild to moderate OA. They were injected in their knees
by PRP for six injections at monthly-intervals.
In our patients, a statistically signiﬁcant improvement was
observed regarding most of the clinical aspects, such as, ten-
derness in joint line, crepitus and range of motion. There
was, also, improvement in the number of patients having hot-
ness, effusion and Baker’s cyst, but this improvement did not
reach a statistically signiﬁcant level.
In this study, there were highly statistically signiﬁcant
improvements in the patient´s perception of pain, knee functionTable 4 Correlation between patients’ ages, BMI and the severity of
osteoarthritis.
Score Age BM
r P r
VAS 0.55 <0.001** 0.2
IKDC 0.32 0.03* 0.9
VAS: visual analogue scale, IKDC: international knee documentation co
* Signiﬁcance at p< 0.05.
** High signiﬁcance at p< 0.001.and quality of life, represented by the duration of inactivity
stiffness, VAS and IKDC score. Better results were achieved
in younger patients and those with short disease duration. This
could be explained by the high percentage of living and vital
cells and therefore the high response potential to the growth
factors. BMI showed a signiﬁcant correlation with VAS and
a highly signiﬁcant negative correlation with IKDC score after
6 PRP injections.
Sampson and colleagues evaluated the effect of 3 monthly
doses of PRP in 14 patients with OA of the knee refractory
to conservative treatment. They observed a linear improve-
ment of VAS and knee injury OA outcome in 60% of patients
at follow-up [25]. The same results were reported byWang and
colleagues [26]. More recently, improvement in all WOMAC
parameters [27,28], pain scores, clinical and functional scores
[29] was reported after three injections of PRP. Intra-articular
PRP injections had a better response in younger patients
[23,24], more active patients [30] and those with low grade
OA [31]. It has been reported that better response rates are evi-
dent in OA patients treated with PRP injections than in those
treated with hyaluronic acid [24,30,32], although a recent study
reported that they have the same efﬁcacy [31].
Regarding musculoskeletal Doppler ultrasound ﬁndings
there was a highly signiﬁcant improvement in synovial
hypertrophy and a signiﬁcant improvement in Doppler activity
(p= 0.04). But, there were no signiﬁcant changes in the ultr-
asonographic grading of cartilage degeneration after PRPpain and functional scores after 6 injections in patients with knee
I Disease duration
P r P
9 0.03* 0.71 <0.001**
6 <0.001** 0.79 <0.001**
mmittee.
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1, meaning that thinning of his cartilage has no longer been
evident during musculoskeletal ultrasound examination.
Actually, the role of PRP in the cartilage repair is a matter
of debate. A recent study reported that qualitative MRIs dem-
onstrated no change per compartment in at least 73% after
PRP injections [29]. But a lot of in vitro studies evaluated
the effect of PRP on chondrocytes; Gaissmaier et al., reported
that addition of human platelet supernatant may accelerate
chondrocyte expansion, even though it can also lead to de dif-
ferentiation [33]. In another study, an autologous conditioned
serum was administered in horses with experimentally induced
OA and reported a signiﬁcant clinical improvement in lame-
ness, decreased synovial membrane hyperplasia, less gross car-
tilage ﬁbrillation and synovial membrane haemorrhage and
increased synovial ﬂuid concentration of interlukin-1 receptor
antagonist. They stated that PRP may inﬂuence the overall
joint homoeostasis, reducing synovial membrane hyperplasia
and modulating the cytokine level, thus leading to an improve-
ment in the clinical outcome, even if only temporarily and
without affecting the cartilage tissue structure and joint degen-
erative progression [34]. Wu et al. investigated the feasibility of
PRP to support chondrogenesis; they found that gelled PRP
provided a 3-dimensional environment for seeded chondro-
cytes and was successfully used to deliver chondrocytes in car-
tilage defects in a rabbit model [35].Mitssuyama and colleagues
reported that PRP promotes human chondrocyte prolifera-
tion, cells expanded with 30% PRP can express chondrocyte
phenotype, and can serve as scaffold for autologous chondro-
cyte implantation that has potential availability for repair of
osteoarthritis with chondral defects [36]. Regarding humans,
an old case report has been described, where plasma rich in
growth factors was used to treat an articular cartilage avulsion
in a soccer player. They reported an accelerated and complete
articular cartilage healing [37]. Recently, it has been stated that
PRP has an anabolic effect on chondrocytes and bone mar-
row-derived stem cells with resulting increase in the cell prolif-
eration and matrix production, as well as an anti-inﬂammatory
effect via down regulation of known catabolic signalling path-
ways [38].
Our study showed that this method of treatment is very safe
as no complications such as infection or fever occurred among
study subjects. Only minor adverse events were detected such
as mild pain at injected area and skin bruises. Patel and col-
leagues reported mild complications such as nausea and dizzi-
ness, which were of short duration [27] and these complications
were not reported in our patients.
In conclusion, from the presented results it was found that
intra-articular injection of PRP is an effective and safe method
for treatment of knee OA. Maximal improvement was seen in
younger patients and those with shorter disease duration.
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